You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究升信達生物(01801.HK)目標價至55元 收支平衡指日可待
阿思達克 03-26 10:33
匯豐研究發表報告指,信達生物(01801.HK)去年下半年收入35億元人民幣,按年升51%,主要受PD-1抑制劑及生物相似藥的強勁增長推動,淨虧損9億元人民幣,相比2022年下半年虧損為11億元人民幣。展望前景,該行對其藥物商業化進展感到樂觀,在有效成本控制下,相信明年EBITDA收支平衡的目標可以達到。 該行指,其年初至今股價下跌8%,現價相當於今年預測市銷率7倍,估值仍然吸引,並預期減重藥GLP-1/GCGR的推出成為未來的催化劑,商業產品擴充將會支持其估值,維持「買入」評級,目標價由53元上調至55元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account